212 related articles for article (PubMed ID: 18336252)
1. Adiponectin and its role in cardiovascular diseases.
Bełtowski J; Jamroz-Wiśniewska A; Widomska S
Cardiovasc Hematol Disord Drug Targets; 2008 Mar; 8(1):7-46. PubMed ID: 18336252
[TBL] [Abstract][Full Text] [Related]
2. Adiponectin--a key adipokine in the metabolic syndrome.
Whitehead JP; Richards AA; Hickman IJ; Macdonald GA; Prins JB
Diabetes Obes Metab; 2006 May; 8(3):264-80. PubMed ID: 16634986
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular actions of adiponectin: pathophysiologic implications.
Maia-Fernandes T; Roncon-Albuquerque R; Leite-Moreira AF
Rev Port Cardiol; 2008 Nov; 27(11):1431-49. PubMed ID: 19227810
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin and adiponectin receptors.
Kadowaki T; Yamauchi T
Endocr Rev; 2005 May; 26(3):439-51. PubMed ID: 15897298
[TBL] [Abstract][Full Text] [Related]
5. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
Goto T; Teraminami A; Lee JY; Ohyama K; Funakoshi K; Kim YI; Hirai S; Uemura T; Yu R; Takahashi N; Kawada T
J Nutr Biochem; 2012 Jul; 23(7):768-76. PubMed ID: 21889885
[TBL] [Abstract][Full Text] [Related]
6. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
Yamauchi T; Kadowaki T
Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S13-8. PubMed ID: 19136982
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism.
Astapova O; Leff T
Vitam Horm; 2012; 90():143-62. PubMed ID: 23017715
[TBL] [Abstract][Full Text] [Related]
8. Adipokines in diabetes and cardiovascular diseases.
Kralisch S; Sommer G; Deckert CM; Linke A; Bluher M; Stumvoll M; Fasshauer M
Minerva Endocrinol; 2007 Sep; 32(3):161-71. PubMed ID: 17912155
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
10. Divergent roles for adiponectin receptor 1 (AdipoR1) and AdipoR2 in mediating revascularization and metabolic dysfunction in vivo.
Parker-Duffen JL; Nakamura K; Silver M; Zuriaga MA; MacLauchlan S; Aprahamian TR; Walsh K
J Biol Chem; 2014 Jun; 289(23):16200-13. PubMed ID: 24742672
[TBL] [Abstract][Full Text] [Related]
11. Modulation of adiponectin as a potential therapeutic strategy.
Lim S; Quon MJ; Koh KK
Atherosclerosis; 2014 Apr; 233(2):721-728. PubMed ID: 24603219
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential.
Zha D; Wu X; Gao P
Endocrinology; 2017 Jul; 158(7):2022-2034. PubMed ID: 28402446
[TBL] [Abstract][Full Text] [Related]
13. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
14. [Adipokines: adiponectin, leptin, resistin and coronary heart disease risk].
Kopff B; Jegier A
Przegl Lek; 2005; 62 Suppl 3():69-72. PubMed ID: 16521924
[TBL] [Abstract][Full Text] [Related]
15. GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.
Xin XM; Zhong MX; Yang GL; Peng Y; Zhang YL; Zhu W
World J Gastroenterol; 2014 Nov; 20(42):15727-35. PubMed ID: 25400456
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin receptors in energy homeostasis and obesity pathogenesis.
Akingbemi BT
Prog Mol Biol Transl Sci; 2013; 114():317-42. PubMed ID: 23317789
[TBL] [Abstract][Full Text] [Related]
17. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents.
Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR
Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896
[TBL] [Abstract][Full Text] [Related]
18. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Barac A; Campia U; Matuskey LA; Lu L; Panza JA
Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin-Resistance in Obesity.
Engin A
Adv Exp Med Biol; 2017; 960():415-441. PubMed ID: 28585210
[TBL] [Abstract][Full Text] [Related]
20. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
